August 21, 2014

FDA About to Greenlight a Drug Banned in Other Countries

pin it button FDA About to Greenlight a Drug Banned in Other Countries

warning fda approved 300x222 FDA About to Greenlight a Drug Banned in Other Countries

by Alliance for Natural Health

Is FDA About to Greenlight a Drug Banned in Other Countries?

If enough people raise their voices in protest, we can prevent it. Action Alert!

Remember the controversial diabetes drug Avandia? In 2010 we told you about two FDA drug safety reviewers who warned the agency that Avandia posed serious risks of heart attack and heart failure when compared with other diabetes drugs. Since then, the drug has been removed from the market in most countries and has been under severe restrictions in the US.

Last Thursday, in a combined meeting of separate FDA advisory committees, 20 of 26 panelists voted to recommend removing or modifying Avandia’s highly restrictive label and distribution system. Five voted to keep the restrictions in place, while one panelist voted to remove the product from the market altogether.

There has been only one large, randomized trial for the safety of rosiglitazone, the drug that is marketed as Avandia. That trial—sponsored by GlaxoSmithKline (GSK), the drug’s manufacturer—was called RECORD (Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes). Serious flaws were found in RECORD’s methodology, its results were questioned, and the trial was widely discredited.

In 2010, FDA required GSK’s RECORD results to be reexamined and re-adjudicated. What was the FDA’s motivation for reviewing Avandia? GSK didn’t request that the drug be reviewed. Could it be, as Steve Nissen suggests in Forbes, because FDA “is seeking to avoid accountability for its role in the Avandia tragedy”? FDA’s official position is that they asked for the re-adjudication because of “the public interest in Avandia, the extensive history of the product, and the continued uncertainty of the risk surrounding this drug.”

Duke University’s Clinical Research Institute (DCRI) was selected for the re-adjudication, and they found that the risk for cardiovascular death, myocardial infarction (MI), and stroke to be virtually the same as the original study concluded. Because these new results reaffirmed GSK’s findings that the drug was no more unsafe than other diabetes products in its class, Thursday’s panelists were sufficiently reassured that the drug was safe enough to lift restrictions.

Unfortunately, other data paint a very different picture:

  • In 2005 and 2006 GSK secretly conducted an analysis of cardiovascular safety of Avandia, and concluded that the drug increased the risk of heart attacks and related events by 30%. Since two-thirds of diabetics eventually die of cardiovascular complications anyway, this 30% hike is terrifying.
  • In 2006 GSK informed the FDA’s Center for Drug Evaluation and Research (CDER) of the secret analysis, but FDA and CDER agreed to conceal this hazard from patients and practitioners.
  • During a public hearing, independent FDA statisticians reported an 80% increased risk of heart attack. Avandia is estimated to have caused 83,000 heart attacks in the United States alone.
  • Adverse effects caused by the drug are currently the subject of over 13,000 lawsuits against GSK. As of July 2010, GSK has agreed to settlements on more than 11,500 of these suits.
  • Last year, GSK pled guilty of criminal conduct, partially for concealing the hazards of Avandia. The company paid a $3 billion fine—the largest in US history.

In addition, the re-adjudication process itself was biased. GSK prepared the study materials before submitting them to Duke for analysis, rather than allowing the university to review the raw data. (On the widespread problem of publication bias, see our article in this issue.)

On top of that, key members of the 2010 advisory committee that decided to place restrictions on Avandia in the first place were not part of the 2013 meeting. Of the twenty-seven member panel, fourteen of the experts were on the panel last time, and they were the people with a more favorable attitude toward Avandia. This is in contrast to the other experts who did not serve on the panel a second time—like Steven Nissen, who was one of the most outspoken critics on the panel. FDA claims all panelists were invited, it does not appear they made a huge effort to ensure their participation; Nissen says he was not re-invited. With all of the big nay-sayers out of the picture, it’s no surprise the panel voted to lift the restrictions on this dangerous drug.

FDA should focus more on advisory panelists who have true conflicts of interest. A 2007 law placed caps on the number of waivers that could be granted allowing experts with conflicts of interest; a 2012 law removed those safeguards. When there are no restrictions on experts with conflicts of interest serving on FDA advisory panels, more drugs with dangerous side effects could certainly enter the market.

Action Alert! The FDA is not obligated to follow its advisory committee’s recommendation, though they usually do so. Moreover, there is no regulatory deadline by which they have to make a decision. If there is enough public pressure, perhaps this will force the FDA to reject the advisory committee’s decision on Avandia—or at least postpone any action indefinitely.Please send your message to the FDA about the dangers of Avandia!

Take Action11 FDA About to Greenlight a Drug Banned in Other Countries

Read the full article here: http://www.anh-usa.org/fda-greenlight-drug-banned

Confessions 20of 20an 20Rx 20Drug 20Pusher FDA About to Greenlight a Drug Banned in Other Countries

Free Shipping Available for this book!


0 commentsback to post

Other articlesgo to homepage

Will India be First Country to Revoke Marketing Licenses for HPV Vaccines?

Will India be First Country to Revoke Marketing Licenses for HPV Vaccines?

Pin It

A petition currently before the Supreme Court of India alleges that the Drugs Controller of India issued licenses for Gardasil and Cervarix without adequate research on safety as directed by the Parliamentary Standing Committee on Health and Family Welfare.

Petition number 558/2012, filed by Kalpana Mehta, Nalini Bhanot and V. Rukmini Rao, seeks to resolve this and several other issues by asking the Supreme Court of India to rescind the licenses for marketing and administration of HPV vaccines, make provisions to identify and treat any girls left with chronic health problems and/or autoimmune disorders after their participation in HPV vaccine trials, blacklist the Program for Appropriate Technology in Health (PATH), and allow no other foreign agencies to have a field presence in India.

Will India be the first country in the world to revoke the marketing licenses for Gardasil and Cervarix? Will the Supreme Court of India move to protect the health and welfare of their young citizens, or the interests of the HPV vaccine manufacturers? Will PATH and similar agencies be banned from operating in India?
Will the victims of adverse reactions to HPV vaccines be located and treated? We can only hope these questions will be answered when the final hearing will take place.

CDC Whistleblower: CDC Covered Up MMR Vaccine Link to Autism in African American Boys

CDC Whistleblower: CDC Covered Up MMR Vaccine Link to Autism in African American Boys

Pin It

A top research scientist working for the Centers for Disease Control and Prevention (CDC) played a key role in helping Dr. Brian Hooker of the Focus Autism Foundation uncover data manipulation by the CDC that obscured a higher incidence of autism in African-American boys.

“We’ve missed ten years of research because the CDC is so paralyzed right now by anything related to autism. They’re not doing what they should be doing because they’re afraid to look for things that might be associated.” The whistleblower alleges criminal wrongdoing of his supervisors, and he expressed deep regret about his role in helping the CDC hide data.

The Cancer Industry is Too Prosperous to Allow a Cure

The Cancer Industry is Too Prosperous to Allow a Cure

Pin It

We have lost the war on cancer. At the beginning of the last century, one person in twenty would get cancer. In the 1940s it was one out of every sixteen people. In the 1970s it was one person out of ten. Today one person out of three gets cancer in the course of their life.

The cancer industry is probably the most prosperous business in the United States. In 2014, there will be an estimated 1,665,540 new cancer cases diagnosed and 585,720 cancer deaths in the US. $6 billion of tax-payer funds are cycled through various federal agencies for cancer research, such as the National Cancer Institute (NCI). The NCI states that the medical costs of cancer care are $125 billion, with a projected 39 percent increase to $173 billion by 2020.

The simple fact is that the cancer industry employs too many people and produces too much income to allow a cure to be found. All of the current research on cancer drugs is based on the premise that the cancer market will grow, not shrink.

John Thomas explains to us why the current cancer industry prospers while treating cancer, but cannot afford to cure it.

800,000 Die from Blindly Trusting Their Doctor’s Prescription for This Pre-Surgery Drug

800,000 Die from Blindly Trusting Their Doctor’s Prescription for This Pre-Surgery Drug

Pin It

European doctors may have caused as many as 800,000 deaths in five years by following the “standard of care” to use beta-blockers in non-cardiac surgery patients—a guideline based largely on discredited science.

Tylenol: The Killer Drug Your Children can Buy

Tylenol: The Killer Drug Your Children can Buy

Pin It

Is there any more doubt that acetaminophen (Tylenol) is the most dangerous over-the-counter drug ever allowed to be sold legally without a prescription? Consider the facts:

Acetaminophen kills almost 500 people a year due to acute liver failure.
Acetaminophen overdose is the leading cause for calls to Poison Control Centers – more than 100,000/year.
Acetaminophen accounts for more than 56,000 emergency room visits, 2,600 hospitalizations.
Acetaminophen poisoning causes nearly 50% of all acute liver failure in the United States.
Acetaminophen is linked to fatal skin reactions.
Acetaminophen causes a two-fold increased risk of blood cancer.
Acetaminophen can cause an increase in autism, attention deficit with hyperactivity, and asthma when used with vaccines.

And yet, any child can walk into a drug store or grocery store and buy it like candy. Alliance for Natural Health brings us the latest bad news on Tylenol:

A study just published in JAMA Pediatrics finds that Tylenol (acetaminophen) taken by women during their pregnancy may raise the risk of ADHD (Attention Deficit Hyperactive Disorder) and similar disorders in their children up to 40%—with the risk increasing the more acetaminophen the mother takes.

read more


Get the news right in your inbox!